Denna sida på svenska

Mattias Carlsten

Assistant professor

Visiting address : M 54, Karolinska Universitetssjukhuset Huddinge 141 86 Stockholm, Sweden
Postal address : Department of Medicine, Huddinge (MedH), H7, Unit for Hematology, M 54, Karolinska Universitetssjukhuset Huddinge 141 86 Stockholm, Sweden
Delivery address : M 54, Karolinska Universitetssjukhuset Huddinge 141 86 Srockholm, Sweden

About me

I received my MD degree from Karolinska Institutet 2007 after conducting studies within the MD/PhD program. Following completion of my medical intership (Forskar-AT) at the Karolinska University Hospital late fall 2009, I defended my PhD thesis at Karolinska Institutet early spring 2010 supervised by Prof. Karl-Johan Malmbergs and Prof. Rolf Kiessling. I then joined the group of Dr. Richard W. Childs at Hematology Branch, NHLBI, NIH (USA) as a Postdoc 2010. Since 2012 I have been doing my residency/fellowship in Internal Medicine/Hematology at Center for Hematology, Karolinska University Hospital, with the exception of a sabatical between 2013-2015 when I was employed as a Staff Scientist with Dr. Childs at the NIH. From 2016, I am a Research Group leader at Center for Regenerative Medicine and Hematology (HERM), Department of Medicine Huddinge, Karolinska Institutet.

Education

2007, MD, Karolinska Institutet

2009, Swedish Medical Practioner License, Karolinska University Hospital

2010, PhD, Karolinska Institutet

2010-2012, Postdoctoral Fellow, Hematology Branch, NHLBI, NIH

2013-2015, Staff Scientist, Hematology Branch, NHLBI, NIH

2012-, Resident/Fellow in Internal Medicine/Hematology, Karolinska University Hospital

2016-, Research Group Leader, HERM, Department of Medicine Huddinge, Karolinska Institutet

Research description

My research focuses on cancer immunotherapy, with a particular focus on how NK cells can be used to treat cancer. With my experience in bench science and clinical medicine, my projects spans from preclinical basic NK cell biology and tumor immunology studies to translational to early phase clinical trials on NK cell-based cancer immunotherapy and stem cell transplantation. A big focus in my lab is currently how genetic engineering of lymphocytes, including NK cells, can be used to further improve the efficacy of cellular cancer immunotherapies.

Academic honors, awards and prizes

2015, SSMF Stora Anslag

2015, Jeanssons Stiftelser Personal Achievement Award

2012, Translational Research Training in Hematology (TRTH) Award

2010, Dean O’Neill Renal Cancer Cell Research Fellowship

2004, MD/PhD program at Karolinska Institutet

2000, Läkarutbildningen med forskningsinriktning (LäFo), Karolinska Institutet

Links

Publications

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Carlsten M, Korde N, Kotecha R, Reger R, Bor S, Kazandjian D, et al
Clinical cancer research : an official journal of the American Association for Cancer Research 2016;22(21):5211-5222

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19
Carlsten M, Levy E, Karambelkar A, Li L, Reger R, Berg M, et al
Frontiers in immunology 2016;7():105-

mRNA Transfection to Improve NK Cell Homing to Tumors
Levy Er, Carlsten M, Childs Rw
Methods in molecular biology (Clifton, N.J.) 2016;1441():231-40

Coordinated expression of DNAM-1 and LFA-1 in educated NK cells
Enqvist M, Ask Eh, Forslund E, Carlsten M, Abrahamsen G, Béziat V, et al
Journal of immunology (Baltimore, Md. : 1950) 2015;194(9):4518-27

Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
Carlsten M, Childs Rw
Frontiers in immunology 2015;6():266-

The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies
Dosani T, Carlsten M, Maric I, Landgren O
Blood cancer journal 2015;5():e321-

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Childs Rw, Carlsten M
Nature reviews. Drug discovery 2015;14(7):487-98

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Korde N, Carlsten M, Lee Mj, Minter A, Tan E, Kwok M, et al
Haematologica 2014;99(6):e81-3

Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers
Ito S, Bollard Cm, Carlsten M, Melenhorst Jj, Biancotto A, Wang E, et al
Molecular therapy : the journal of the American Society of Gene Therapy 2014;22(7):1388-95

Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling
Wennerberg E, Sarhan D, Carlsten M, Kaminskyy Vo, D'arcy P, Zhivotovsky B, et al
International journal of cancer 2013;133(7):1643-52

Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells
Enqvist M, Nilsonne G, Hammarfjord O, Wallin Rp, Björkström Nk, Björnstedt M, et al
Journal of immunology (Baltimore, Md. : 1950) 2011;187(7):3546-54

Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome
Carlsten M, Baumann Bc, Simonsson M, Jädersten M, Forsblom Am, Hammarstedt C, et al
Leukemia 2010;24(9):1607-16

Natural killer cell-mediated lysis of freshly isolated human tumor cells
Carlsten M, Malmberg Kj, Ljunggren Hg
International journal of cancer 2009;124(4):757-62

Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells
Carlsten M, Norell H, Bryceson Yt, Poschke I, Schedvins K, Ljunggren Hg, et al
Journal of immunology (Baltimore, Md. : 1950) 2009;183(8):4921-30

Regulation of interleukin-4 signaling by extracellular reduction of intramolecular disulfides
Curbo S, Gaudin R, Carlsten M, Malmberg Kj, Troye-blomberg M, Ahlborg N, et al
Biochemical and biophysical research communications 2009;390(4):1272-7

Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype
Fauriat C, Andersson S, Björklund At, Carlsten M, Schaffer M, Björkström Nk, et al
Journal of immunology (Baltimore, Md. : 1950) 2008;181(9):6010-9

NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg Kj, Bryceson Yt, Carlsten M, Andersson S, Björklund A, Björkström Nk, et al
Cancer immunology, immunotherapy : CII 2008;57(10):1541-52

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients
Hanson Mg, Ozenci V, Carlsten Mc, Glimelius Bl, Frödin Je, Masucci G, et al
Cancer immunology, immunotherapy : CII 2007;56(7):973-84

DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells
Carlsten M, Björkström Nk, Norell H, Bryceson Y, Van Hall T, Baumann Bc, et al
Cancer research 2007;67(3):1317-25

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity
Norell H, Carlsten M, Ohlum T, Malmberg Kj, Masucci G, Schedvins K, et al
Cancer research 2006;66(12):6387-94

IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism
Malmberg Kj, Levitsky V, Norell H, De Matos Ct, Carlsten M, Schedvins K, et al
The Journal of clinical investigation 2002;110(10):1515-23

The core promoter of human thioredoxin reductase 1: cloning, transcriptional activity, and Oct-1, Sp1, and Sp3 binding reveal a housekeeping-type promoter for the AU-rich element-regulated gene
Rundlöf Ak, Carlsten M, Arnér Es
The Journal of biological chemistry 2001;276(32):30542-51

Prominent expression of the selenoprotein thioredoxin reductase in the medullary rays of the rat kidney and thioredoxin reductase mRNA variants differing at the 5' untranslated region
Rundlöf Ak, Carlsten M, Giacobini Mm, Arnér Es
The Biochemical journal 2000;347 Pt 3():661-8

Show all publications